In August 2005, Agentase LLC was acquired by ICX Technologies. Agentase develops biocatalyst preparations. Agentase works with a variety of federal agencies and corporate clients to develop enzyme-based systems tailored to specific performance criteria. Our technology addresses the perceived limitations of enzyme catalysis such as short catalytic lifetimes that restrict product shelf life and reduce catalyst productivity, acute environmental sensitivity that limits the range of acceptable conditions for catalysis, and vulnerability to thermal denaturation by developing novel application vehicles capable of protecting enzymes from adverse environments while enhancing their utility in a specific application.
